The author links MDD to an exaggerated ‘give-up’ response, mediated by excessive production of the opioid dynorphin, offering novel insights into potential treatments for depression.

The theory begins by categorizing the basic psychological responses to stress: fight, flight, freeze, faint, and disengage. In the context of depression, the disengage or ‘give-up’ response becomes dominant and prolonged. This response, biologically supported by the release of dynorphin, leads to a state of mental and physical inertia, where individuals struggle to engage with life or resolve their underlying stressors.

Dynorphin, an opioid produced in the brain and body, plays a crucial role in this theory. While opioids generally help regulate survival responses, excessive dynorphin production disrupts normal functioning, resulting in the characteristic symptoms of depression: low energy, lack of motivation, and persistent rumination on problems.

The theory highlights the limitations of current treatments, such as selective serotonin reuptake inhibitors (SSRIs). Although SSRIs can alleviate stress-related effects on the brain by increasing serotonin levels, they often do not address the underlying dynorphin-driven mechanism of depression. Moreover, SSRIs can blunt emotional responses, making individuals feel robotic and disconnected. Long-term use may also desensitize the serotonin system, leading to diminished efficacy and side effects such as sexual dysfunction.

The author emphasizes the potential of targeting dynorphin signaling as a more effective treatment approach. Recent developments in pharmaceutical research include drugs designed to block dynorphin receptors. These drugs, though not originally developed with this theory in mind, align with the proposed mechanism and could offer improved outcomes for depression patients. Further research is needed to refine these drugs and explore their efficacy.

In addition to drug development, the theory suggests the importance of addressing the chronic stressors that trigger excessive dynorphin production. Therapeutic interventions that help individuals resolve or reframe their stressors could complement pharmacological treatments, providing a more holistic approach to managing depression.

In summary, the author’s theory redefines depression as a disorder rooted in the excessive activation of the ‘give-up’ response, mediated by dynorphin. This perspective bridges psychological and biological explanations, offering a cohesive framework for understanding MDD. By targeting dynorphin and addressing chronic stressors, this approach has the potential to revolutionize treatment and improve outcomes for those living with depression.